u-0126 and Drug-Related-Side-Effects-and-Adverse-Reactions

In acute ischemic stroke, the only FDA-approved drug; recombinant tissue plasminogen activator (rt-PA) is limited by restricted time-window due to an enhanced risk of hemorrhagic transformation which is thought to be caused by metalloproteinase (MMP). In experimental stroke inhibitors of the mitogen-activated protein kinase kinase extracellular signal-regulated kinase kinase (MEK) 1/2 pathways reduce the MMPs. This study evaluated whether a MEK1/2 inhibitor in combination with rt-PA can prevent the detrimental effects of delayed rt-PA therapy in stroke. Thromboembolic stroke was induced in C57 black/6J mice and the MEK1/2 inhibitor U0126 was administrated 3.5 h and rt-PA 4 h post stroke-onset. Treatment with rt-PA demonstrated enhanced MMP-9 protein levels and hemorrhagic transformation which was prevented when U0126 was given in conjunction with rt-PA. By blocking the MMP-9 with U0126 the safety of rt-PA administration was improved and demonstrates a promising adjuvant strategy to reduce the harmful effects of delayed rt-PA treatment in acute ischemic stroke.

Topics: Animals; Butadienes; Disease Models, Animal; Drug Discovery; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Ischemic Stroke; Male; Matrix Metalloproteinase 9; Mice; Mitogen-Activated Protein Kinase Kinases; Nitriles; Signal Transduction; Tissue Plasminogen Activator; Treatment Outcome